I
nterferon-␥ (IFN-␥) is a lymphokine with both antiproliferative and immunomodulatory antitumor effects that is used clinically for the treatment of melanoma and other advanced malignancies. [1] [2] [3] [4] [5] [6] [7] Post phase I/II trials have demonstrated variable clinical response rates depending upon the dose of IFN-␥, route of administration, and type of cancer. 8 -14 Generally, higher doses of the recombinant protein have shown some clinical efficacy; however, treatment is limited by systemic toxicity. The use of IFN-␥ as an anti-cancer therapeutic has three potential mechanisms of action. A high concentration of IFN-␥ at the tumor site has been shown to induce major histocompatibility complex (MHC) class I and class II expression on tumor cells [15] [16] [17] [18] [19] [20] that is associated with enhanced tumor antigen presentation. Melanomas with enhanced class I and class II expression have been shown to be better targets for anti-melanoma cytotoxic T lymphocytes when assayed in vitro. 21 IFN-␥ displays a direct immunostimulatory effect by inducing the maturation and activation of cytotoxic T cells, macrophages, and natural killer cells, which are required for a strong antitumor response. 22 Lastly, IFN-␥ has been shown to have direct antiproliferative effects on tumor cells. 23, 24 The administration of IFN-␥ localized within the tumor microenvironment may show clinical efficacy without the limitation of systemic toxicity. Preclinical animal studies using recombinant IFN-␥ alone or in combination with interleukin-2 (IL-2) have demonstrated that local injection within the tumor mass can stimulate a strong protective response for further tumor challenge and even direct tumor regression. 25, 26 An alternative approach is the delivery into and expression of the IFN-␥ gene by the tumor cells themselves. Several investigators have demonstrated that in vitro IFN-␥ gene-modified mouse tumor cell vaccinations can generate protective responses from unmodified tumor cell challenges as well as a regression of established tumors. [27] [28] [29] [30] [31] Similar results have been demonstrated for other cytokines, such as IL-2, IL-4, macrophage colonystimulating factor, and GM-CSF. [33] [34] [35] [36] [37] [38] [39] [40] Several clinical trials exploring the safety of injections with IFN-␥ gene-transduced autologous irradiated tumor cells re-veal a lack of toxicity; however, the ex vivo processing of tumors is not successful in treating the majority of patient candidates. 16 Issues associated with a high failure rate in establishing tumor cell lines and with lengthy manufacturing times have made this approach less attractive. Recent preclinical studies in mice have shown the ability of a high titer retroviral vector preparation to transduce as much as 30% of recovered cells from a 25-40 mm 3 subcutaneous (s.c.) tumor nodule; the level of in vivo transduction directly correlated with the in vivo efficacy of the therapy. 41 Direct injection of an adenoviral vector has been shown to be effective in regional and systemic antitumor responses in several mouse tumor model systems. [42] [43] [44] In light of these observations, we have investigated the potential of intralesional [45] [46] [47] injections to deliver an immunotherapeutic gene directly into tumor cells in situ. In addition, we evaluated the use of polycationic compounds as transduction enhancers for retroviral vectors.
Objective
To evaluate the safety of human IFN-␥ vector administered by direct intralesional injection in patients with metastatic cancer.
MATERIALS AND METHODS

Patient characteristics
Patients with metastatic cancer for which standard treatment measures do not exist and who were Ն18 years of age with an expected survival of Ն3 months were entered into trial. Patients were required to have at least one tumor nodule peripherally located and accessible by injection between the size of 2-5 cm 2 . They also had to demonstrate an increase in growth of Ն25% within 8 weeks prior to study entry. Stable performance status (Eastern Cooperative Oncology Group score of 0 or 1), a hematocrit of Ն30%, a white blood cell count of Ն3000/mm 3 , a platelet count of Ն90,000/mm 3 , serum glutamic oxaloacetic transaminase and serum glutamic pyruvic transaminase of more than three times the upper limit of normal, bilirubin of Ͼ2.0 mg/dL, and prothombin time/partial thromboplastin time in normal limits were required. Patients were required to have negative serology for HIV, hepatitis B, and hepatitis C. Signed informed consent according to institutional policy was required. Patients with leukemia, lymphoma, myeloma, autoimmune disease, organic brain syndrome, or active infection were excluded. Pregnant or lactating women and patients who received prior cancer vaccines were excluded. Prior chemotherapy and radiotherapy were required to be completed within 4 weeks of study treatment, and no prior radiotherapy encompassing the treatment lesions was allowed. No investigational agents were allowed to be administered within 30 days of treatment.
Retroviral vector
The retroviral vector containing the human IFN-␥ gene used in the clinical trial has been described previously. 48, 49 Briefly, the IFN-␥ cDNA was isolated by polymerase chain reaction (PCR) from activated Jurkat cell mRNA and inserted into the pBluescript II-SK ϩ plasmid (Strategene, La Jolla, Calif). The IFN-␥ cDNA was excised and subcloned into the XhoI and ClaI sites of an N2-based vector backbone derived from the Moloney murine leukemia virus to generate the proviral vector plasmid. The Moloney murine leukemia virus long terminal repeat (LTR) controls the expression of the IFN-␥ gene, and an internal simian virus 40 promoter drives the expression of the neomycin resistance selectable marker. This construct was cotransfected with a vesicular stomatitis virus-␥ protein expression vector into an amphotropic canine packaging cell line, DA, and the resulting supernatant was used to generate vector-producing cell lines (VPCLs) from the DA packaging cell line. Individual clones were isolated by dilution cloning and characterized. The VPCL was tested for sterility, mycoplasma, growth kinetics, titer production levels, transfer of expression, and generation of replication-competent retrovirus.
Retroviral vector production
A vial of the IFN-␥ VPCL was thawed from a working cell bank and grown in 225-cm 2 flasks at 37°C using Dulbecco's modified Eagle's medium high-glucose supplemented with 15% fetal bovine serum. 48 The cells were expanded for several days prior to supernatant collection and harvested once a day for ϳ5 days. Approximately 200 L of crude supernatant were harvested. The vector supernatant was clarified, concentrated, and diafiltered with an isotonic equilibration buffer as described previously. 41 The vector was purified over a Sephacryl S-500 size exclusion column (Pharmacia, Uppsala, Sweden), concentrated further using tangential flow ultrafiltration, and formulated in a solution containing lactose, human serum albumin, and buffer. This material was then tested for contaminating replication-competent retrovirus, sterility, and titer.
Patient treatment routine and evaluation
Ours was an open label, randomized, phase I study in which patients were entered into one of three treatment groups (four patients per group). Group 1 patients received 0.3 mL of IFN-␥ retroviral vector and no cation, group 2 patients received 0.3 mL of IFN-␥ retroviral vector and hexadimethrine bromide, and group 3 patients received 0.3 mL of IFN-␥ retroviral vector and protamine sulfate cation. Each patient received a single daily injection for 5 consecutive days with the IFN-␥ vector formulation. The total dose of vector was 1.5 ϫ 10 8 colony-forming units, which was the maximum vector concentration possible at initiation of the trial. At 3 days after the last injection, patients underwent resection of the injected tumor to determine the integration of retroviral vector DNA and IFN-␥ protein expression. A routine physical exam, chemistry, complete blood count and differential, and coagulation studies were performed at baseline and weekly after the first injection for 12 weeks. Urine analysis and computed tomography scans at the original site of disease, brain, chest, and abdomen were done at baseline and at week 12.
Determination of in vivo gene transduction by enzyme-linked immunospot (ELISPOT) assay
Evidence for in vivo gene transduction was determined by ELISPOT assay for the secretion of IFN-␥ protein by tumor cells in vitro. 48 Under sterile conditions, tumor tissue was mechanically dissociated and incubated with collagenase and deoxyribonuclease to obtain a single-cell suspension. The viability of the cells was determined by trypan blue exclusion. Tumor cells were serially diluted (1-5 ϫ 10 4 to 40 cells/well) and plated in triplicate onto a 96-well plate precoated with a mouse anti-human IFN-␥ monoclonal antibody (Endogen, Woburn, Mass). Each 96-well plate included an in vitro IFN-␥ retroviral vector-modified melanoma cell line as a positive control and unmodified melanoma cell line as a negative control. Following overnight incubation in Dulbecco's modified Eagle's medium high-glucose media supplemented with 10% fetal bovine serum at 37°C in a 5% CO 2 humidified incubator, the cells were removed, and the wells washed twice with phosphate-buffered saline. The wells were then incubated with rabbit anti-human IFN-␥ polyclonal antibodies (Endogen), washed, and followed with a final incubation with goat anti-rabbit immunoglobulin polyclonal antibodies conjugated with horseradish peroxidase ( 
Determination of in vivo gene transduction via PCR assay
Tumor cells from resected lesions were analyzed by PCR for the presence of provector sequences. A portion of the singlecell preparation used in the ELISPOT analysis was processed for DNA isolation using a urea-based lysis buffer and phenolchloroform extraction. The DNA was screened with a primer set that amplifies a region of the IFN-␥ provector spanning the LTR and ⌿ packaging sequence. A total of 10 L of each PCR was blotted onto nylon membranes using a dot blot apparatus and hybridized with a 32 P-endlabeled oligonucleotide probe. The oligonucleotide probe is a 19-mer that is specific for an internal region of the LTR-⌿ sequence. The blot was exposed to x-ray film, and results were read as the number of positives per number of reactions.
Replication competent retrovirus assay
The detection of replication-competent retrovirus in vivo has already been described in detail elsewhere. 49 Briefly, total DNA was isolated from peripheral blood lymphocytes isolated from patient blood using standard recombinant DNA protocols. The DNA was analyzed by PCR using a primer set design to amplify retroviral vector sequences. The presence of retroviral vector DNA is indicated by the appearance of a 123-base amplicon.
Statistics
Patient demographics, adverse events, and tumor response were summarized. The survival of patients was analyzed by Kaplan-Meier analysis. Significance was determined by Wilcoxon and log-rank tests.
RESULTS
A total of 14 patients were registered into trial from June 6, 1995 to October 6, 1995. One patient was not entered into trial when baseline workup revealed that the sole proposed injection site was a nonmalignant cyst. The data on this patient are not included in this analysis. A total of 11 patients had stage IV melanoma, 1 patient had stage III melanoma, and 1 patient had stage IV breast cancer. Patient age, sex, site of injection, diameter of injected site, prior treatment, and sites of other disease are shown in Table 1 . All patients received a minimum of five daily injections. Of the 13 patients, 12 underwent surgical resection of the injected lesion. One patient (1017) had cancer progression prior to surgery and did not undergo surgical resection. All patients were evaluable for survival.
Adverse events
Six grade 3-4 adverse events were reported. Two patients developed grade III toxicity (abdominal pain in patient 1016 and hypercalcemia in patient 1017). Four patients developed grade IV toxicity (three deaths and one paraplegia). All grade III/IV toxicities were related to metastatic disease or cancer progression. No adverse events were attributed to the study vector. The postoperative adverse events that occurred were related to surgery. Three patients died during the 12-week study period due to progressive disease. No hematopoietic or cardiac dysfunction was observed during the study period. No samples prepared for injection (n ϭ 65) contained replication-competent retrovirus.
DNA integration
A total of 12 patients underwent tumor resection to remove the injected lesion to determine the level of retroviral vector transduction in situ. Of the samples, 10 contained a sufficient number of viable cells after mechanical and enzymatic dissociation for ELISPOT analysis. Transduction was believed to have occurred if Ͼ2% of cells were positive for IFN-␥ expression by ELISPOT assay based on results in which two noninjected melanoma tumors were processed and assayed using the protocol described above (J.M.R., unpublished data). Three samples (1001, 1007, and 1012) showed evidence of in vivo transduction as determined by this assay (see Table 2 ). In addition, the number of IFN-␥-secreting cells was titratable and was directly proportional to the number of cells plated per well, further verifying the results (see Fig 1) . One sample was equivocal, with a 1.8% level of transduction (1005). Six samples showed no evidence of transduction (Ͻ2%). Control samples (1014C and ST008) showed 1.5% and 2.0% transduction. Insufficient patients were studied to evaluate the use of different cations. One of five patients transduced with no cation showed evidence of DNA transduction compared with one of four patients who were injected with hexadimethrine bromide and one of four patients who were injected with protamine sulfate. The number of viable cells recovered per sample was a variable percentage (5-70%) of the estimated total number of cells harvested (ϳ1 ϫ 10 8 cells/cm 3 ), and evidence of transduction was not correlated to the number or viability of the cells recovered (J.M.R., unpublished data).
The first two patient samples were tested by PCR for retroviral DNA integration. Patient 1001 was negative and patient 1003 was positive for vector as shown in Figure 2 . The DNA of these two patients was isolated from the tumor cells and amplified as described in Materials and Methods. Lanes 1-6 in Figure 2 are replicate blots of the same PCR. Lanes 7-8 are the samples spiked with five copies of a positive control, genomic MdMA6 DNA. Negative control reactions contained DNA from normal peripheral blood mononuclear cells. The DNA isolated from patient 1001 resulted in no amplification even in those samples that were spiked with the positive control MdMA6 DNA, suggesting the presence of an inhibitor of the PCR. The purified DNA pellets had a brown tint, which may suggest that melamine might have copurified with the DNA; however, this possibility was not confirmed with further analysis. Patient 1003 was positive in that the blot intensity of the patient DNA sample alone was as high as the intensity of the positive control of five copies of MdMA6 DNA. Subsequent studies (T.F. and J.M.R., unpublished data) have demonstrated that the addition of IFN-␥ retroviral *Breast carcinoma tumor. †Samples 1014C and ST008 are uninjected melanomas put through the mechanical and enzymatic dissociation process to determine ELISPOT assay background levels.
BCNU, N,NЈ-bis(2-chloroethyl)-N-nitrosourea.
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vector to uninjected tumors just prior to processing into a single-cell suspension also tested highly positive by the PCR method. Because it could not be determined whether the positive PCR results were related to actual in vivo transduction and to an integration of retroviral vector DNA or were from free vector particles present in the research tissue, PCR analyses of the other samples were not performed.
Patient response
No radiographic tumor responses were seen at sites distal from the injected tumor. Progressive response of the injected tumor was considered unevaluable because the injected lesion was resected 8 days after the first injection. One patient with stage III disease had no evidence of disease following resection of the injected lesion. He continues to survive without evidence of disease at 517 days postinjection. The patient with stage IV breast cancer (1013) had no evidence of disease after surgical resection; however, disease recurred in a supraclavicular lymph node at 333 days postinjection.
A comparison of survival and evidence of DNA transduction by ELISPOT assay in the melanoma patients revealed that the three patients with Ͼ2% activity had a median survival of 528 Ϯ 10 days. All three of these patients remain alive, whereas none of the patients who did not show DNA transduction survived for Ͼ333 days. 
DISCUSSION
Direct injection of the retroviral vector was well tolerated, particularly in patients showing Ͼ2% activity by ELISPOT assay. The patient sample size was small, but there did not appear to be a relationship between the use of a polycation and an increased efficiency of tumor cell transduction by the IFN-␥ retroviral vector. These results are consistent with data in mouse tumor models that show that transduction in situ is not enhanced with the additional of polycations. 41 Replication-competent retrovirus was not identified in any samples prepared for injection. Transduction in situ by IFN-␥ retroviral vector was observed; however, interpretation of the efficiency of transduction required caution. First, dead cells and cellular debris may have decreased the plating efficiency of the recovered tumor cells and interfered with an accurate determination of the number of IFN-␥-secreting cells in the ELISPOT assay. This possibility was tested by assaying a noninjected tumor module that was spiked with the IFN-␥-secreting control melanoma cell line. The expected number of spots were observed under several concentrations of cells plated per well, suggesting that any decrease in the accuracy of detecting IFN-␥-secreting cells was minimal. The low viability of the recovered cells may have been the result IFN-␥ expression and secretion in vivo prior to resection of the injected tumor. Alternatively, the mechanical and enzymatic processing may have contributed to significant cell death. Unfortunately, only a small number of untreated lesions were available for the pretesting of the processing protocol to determine whether this was the cause of cell death. Preliminary assay development used a primary human melanoma cell line that had been transduced in vivo with the same retroviral vector used in the clinical trial. These cells were a homogenous population of cells secreting relatively high levels of IFN-␥, resulting in well-defined spots in the assay. In addition, these cells were cultured in log-phase growth in vitro prior to plating. In comparison, cells derived from clinical samples were a heterologous population. The processing of resected lesions primarily resulted in a large number of tumor cells, but some samples contained contaminating lymphocytes, fibroblasts, and other cell types. The most likely source of IFN-␥ from the infiltrate would be from activated T cells. The removal of potentially contaminating IFN-␥-secreting T cells was accomplished by harvesting adherent cells only from ELISPOT analysis. In addition, sample 1014 was assayed with contaminating lymphocytes added back to the test, and no increase in positive spots was observed. These observations suggest that false positive results from infiltrating cells within the tumor are not likely. Overall cell viability after resection, shipping, and processing ranged from 5% to 70%; cells were not precultured in vitro prior to assaying.
The relative level of background spots in the assay was estimated using two untreated and injected tumors. One of these control tumors was from a single patient in which an injected and untreated lesion was resected. The number of spots from the injected lesion was comparable with the number observed with the untreated control lesion. The lack of patients with two s.c. lesions precluded the use of an untreated tumor as a background control with all samples tested. However, the number of spots observed was titratable in the three patients that were considered positive (see Fig 1) .
Finally, IFN-␥ has been shown to have a direct cytotoxic or cytostatic effect on tumor cell proliferation in vitro. The transduction and expression of IFN-␥ in situ may have contributed to the low viabilities and to the level of infiltrating lymphocytes in some of the samples. All of these factors can complicate the direct interpretation of the ELISPOT data.
The detection of in vivo transduction was originally to be determined both by the ELISPOT and PCR assays. The ELISPOT would be a functional assay to directly measure the number of IFN-␥-secreting tumor cells recovered from the resected lesion. The overall sensitivity of this assay is low because it is dependent upon the plating efficiency of the control melanoma and sample tumor cells. As an alternative, more sensitive method to determine in vivo transduction, a PCR-based assay was also developed to detect retroviral vector sequences in the genomic DNA isolated from the resected tumor cells. The PCR assay was estimated to be able to detect one positive cell per 10 5 cells tested. Patient 1001 was determined to be negative, and patient 1003 was positive by this assay, which directly conflicts with the ELISPOT data. Spiking sample 1001 with a positive control DNA (MdMA6) resulted in no amplification of the expected DNA fragment, suggesting that an inhibitory compound was coisolated with the DNA. This observation is consistent with those reported in other preclinical trials in which PCR was used to determine whether vector transduction 47 or transfection 50 -52 had occurred in vivo. The highly positive PCR result observed with sample 1003 suggested that DNA from the IFN-␥ retroviral vector may be contaminating the DNA isolated from the Figure 2 . PCR analysis of resected tumor cells to detect retroviral vector sequences. Resected tumor nodules were mechanically and enzymatically dissociated to yield a suspension of single cells. Next, cells were processed, and genomic DNA was purified. A total of 1 g of purified DNA from each sample was PCR amplified with a primer set that spanned the retroviral 5Ј-LTR to ⌿ packaging signal. An aliquot of the amplified DNA was transferred to a nylon membrane and probed with a 32 P-labeled oligonucleotide sequence for the 5Ј-LTR-⌿ region (columns 1-6). As an internal control for inhibitors of amplification, samples of DNA were spiked with five copies of MdMA6 genomic DNA containing the 5Ј-LTR-⌿ sequence (columns 7 and 8). DNA from normal human peripheral blood mononuclear cells was used in the control reaction.
tumor cells. Retroviral vectors can contain low levels of DNA in addition to the abnormal RNA genome, as a result of low levels of reverse transcriptase within the viral particle. 53 This result was confirmed in a control study in which clinical grade IFN-␥ retroviral vector was added to an untreated tumor nodule just prior to mechanical dissociation (see Fig 2) . The sample shown here was highly positive for vector DNA despite no transduction. These data are in contrast to those reported by others, 47, 50 in which PCR was used to determine transduction in vivo. These studies assayed preand posttreatment biopsies and demonstrated positive PCR signals in the posttreatment samples only. However, these data must be interpreted carefully, because no untreated samples were spiked with vector during DNA preparation to insure that the positive results were not simply from contaminating vector DNA. Our observations are consistent with PCR data from animal studies in which the site of injection was still highly positive for vector at 21 days postinjection without any direct evidence indicating that in vitro transduction had occurred (J.M.R. and T.F., unpublished data). Similar data were observed for DNA vectors. 54 Taken together, these observations suggested that the reliability of using a PCR-based assay to determine transduction in situ was questionable; consequently, this type of assay was not performed on the other study patients.
Animal studies 48 suggest that the antitumor effect related to IFN-␥ retroviral vector injection is correlated with the number of injections and the titer of the retroviral vector preparation. Systemic antitumor effects in metastatic tumor animal models have been shown following direct injection of a single peripherally located tumor. Studies in which animals are given an intravenous and s.c. tumor cell inoculation concurrently have demonstrated that regional treatment of the solid s.c. tumor nodule only with a course of direct intralesional injections with either IFN-␥ or IL-2 retroviral vector results in significant regression of the s.c. lesion and in a significant decrease in the number of lung tumor cell foci (our manuscript in preparation).
IFN-␥ activates monocytes; stimulates lymphokineactivated killer activity, B-cell proliferation, and differentiation; activates T cells; and stimulates T-cell proliferation. These activities combine to result in an induction of tumor regression in animal models. 39 Systemic therapy in humans with IFN-␥ has been shown to improve survival in an adjuvant setting following surgery for melanoma patients with deep primary (T4) or regionally metastatic (N1) melanoma. Our previous clinical studies 55 reveal that transduction with the IFN-␥ retroviral vector induces the expression of MHC class I and MHC class II surface antigen.
Because the group of melanoma patients studied were heterogenous with respect to the stage of disease and because the number of patients studied was small, no conclusions regarding correlation of the IFN-␥ retroviral vector injection with survival can be made. Furthermore, one would have expected local tumor regression at the site of injection if the prolonged survival in patients with Ͼ2% activity was solely related to IFN-␥ retroviral vector injection. Nevertheless, further clinical research using multiple 5-day courses of therapy, combination therapy with systemically administered cytokines (i.e., IL-2), and/or treatment of patients with an earlier stage of disease or less extensive disease is indicated. These results are an improvement logistically to our previous results 50 in which autologous tumor cells were harvested, expanded, transduced with IFN-␥, and irradiated ex vivo before injection into the patients. In that trial, only 5 of 58 patients were able to be injected due to the complexity of expanding tumor cells in vivo, whereas in this trial, patients were not excluded from treatment due to the difficulty of cell expansion.
In 
